Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1971 1
1972 2
1973 13
1974 8
1975 10
1976 15
1977 12
1978 14
1979 10
1980 19
1981 9
1982 16
1983 21
1984 22
1985 14
1986 20
1987 18
1988 14
1989 28
1990 34
1991 27
1992 23
1993 33
1994 41
1995 43
1996 31
1997 35
1998 42
1999 46
2000 41
2001 66
2002 64
2003 55
2004 51
2005 54
2006 66
2007 77
2008 68
2009 43
2010 57
2011 61
2012 70
2013 62
2014 79
2015 81
2016 88
2017 77
2018 70
2019 85
2020 78
2021 97
2022 86
2023 73
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

2,084 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Mixed Cellularity Classic Hodgkin Lymphoma"
Page 1
Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM. Ansell SM. Mayo Clin Proc. 2015 Nov;90(11):1574-83. doi: 10.1016/j.mayocp.2015.07.005. Mayo Clin Proc. 2015. PMID: 26541251 Review.
This disease represents approximately 11% of all lymphomas seen in the United States and comprises 2 discrete disease entities--classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Within the subcategorization o …
This disease represents approximately 11% of all lymphomas seen in the United States and comprises 2 discrete disease entities …
Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM. Ansell SM. Am J Hematol. 2022 Nov;97(11):1478-1488. doi: 10.1002/ajh.26717. Epub 2022 Sep 19. Am J Hematol. 2022. PMID: 36215668 Free article.
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually and representing approximately 10% of all lymphomas in the United States. ...Nodular sclerosis, mixed cellularity, lymphocyte …
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8540 new patients annually …
Hodgkin lymphoma.
Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL. Connors JM, et al. Nat Rev Dis Primers. 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6. Nat Rev Dis Primers. 2020. PMID: 32703953 Review.
Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and numerous immune effector cells in the tumour microenvironment. ...Diagnosis is based on histological and immunohistochemical analyses of tissue from a lymph node biopsy; the t …
Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and numerous immune effector cells in t …
Hodgkin lymphoma: Pathology and biology.
Mathas S, Hartmann S, Küppers R. Mathas S, et al. Semin Hematol. 2016 Jul;53(3):139-47. doi: 10.1053/j.seminhematol.2016.05.007. Epub 2016 May 13. Semin Hematol. 2016. PMID: 27496304 Review.
The Hodgkin and Reed-Sternberg (HRS) tumor cells of classical Hodgkin lymphoma (HL), as well as the lymphocyte predominant (LP) cells of nodular lymphocyte predominant HL (NLPHL), are derived from mature B cells. ...The bi- or multinucleated Reed-Sternberg ce …
The Hodgkin and Reed-Sternberg (HRS) tumor cells of classical Hodgkin lymphoma (HL), as well as the lymphocyte predomin …
How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA, Engert A. Eichenauer DA, et al. Blood. 2020 Dec 24;136(26):2987-2993. doi: 10.1182/blood.2019004044. Blood. 2020. PMID: 32877522 Free article. Review.
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with distinct pathologic and clinical characteristics. Unlike the malignant cells in classical Hodgkin lymphoma, the disease-defining lymphocyte-predominant …
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with distinct pathologic and clinical …
Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Ansell SM. Ansell SM. Am J Hematol. 2020 Aug;95(8):978-989. doi: 10.1002/ajh.25856. Epub 2020 Jun 8. Am J Hematol. 2020. PMID: 32384177 Free article.
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8480 new patients annually and representing approximately 10% of all lymphomas in the United States. DIAGNOSIS: Hodgkin lymphoma is composed of two disti …
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8480 new patients annually …
Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation.
Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Fan Z, et al. Am J Surg Pathol. 2003 Oct;27(10):1346-56. doi: 10.1097/00000478-200310000-00007. Am J Surg Pathol. 2003. PMID: 14508396
Prominent sclerosis was identified in approximately 20% of cases and was frequently seen in recurrent disease. Clinical follow-up was obtained on 56 patients, including 26 patients who had not had recurrence of disease and 30 patients who had recurr …
Prominent sclerosis was identified in approximately 20% of cases and was frequently seen in recurrent disease. Clinical follow …
Hodgkin lymphoma.
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J; NCCN Hodgkin Lymphoma. Hoppe RT, et al. J Natl Compr Canc Netw. 2011 Sep 1;9(9):1020-58. doi: 10.6004/jnccn.2011.0086. J Natl Compr Canc Netw. 2011. PMID: 21917626 No abstract available.
Hodgkin's disease.
Desforges JF, Rutherford CJ, Piro A. Desforges JF, et al. N Engl J Med. 1979 Nov 29;301(22):1212-22. doi: 10.1056/NEJM197911293012205. N Engl J Med. 1979. PMID: 388217 Review.
During the past two decades, new approaches to the diagnosis and treatment of Hodgkin's disease have contributed to improved rates of survival and probable cure. Currently, patients with Hodgkin's disease are treated according to the stage and symptoms …
During the past two decades, new approaches to the diagnosis and treatment of Hodgkin's disease have contributed to improved r …
A review of pathobiology and therapies for classic Hodgkin lymphoma.
Khan M, Hagemeister F, Wang M, Ahmed S. Khan M, et al. Blood Rev. 2022 Sep;55:100949. doi: 10.1016/j.blre.2022.100949. Epub 2022 Mar 25. Blood Rev. 2022. PMID: 35396126 Review.
Hodgkin lymphoma can be classified as classical Hodgkin lymphoma (cHL) based on the presence of hallmark Hodgkin and Reed-Sternberg cells. ...
Hodgkin lymphoma can be classified as classical Hodgkin lymphoma (cHL) based on the presence of hallmark Hodg …
2,084 results